Data / Federal awards / NAICS 541715 / ISOLA THERAPEUTICS INC
ISOLA THERAPEUTICS INC: 3 federal contract awards, $7.5 million obligated (FY2024 to FY2027)
Updated October 6, 2026. Source: USAspending.gov.
ISOLA THERAPEUTICS INC (UEI M3QDM72NME75), Minneapolis, MN, received 3 federal prime contract awards with $7.5 million obligated in fiscal years 2024 to 2027, from 1 agency under 2 NAICS codes. Its largest buyer is Department of Health and Human Services ($7.5 million) and its largest code is NAICS 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology).
The request: Every federal contract awarded under NAICS 541715, with the winner, the agency and the value. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every federal contract award on USAspending.gov and every open opportunity on SAM.gov, and this page is that reading. Ask for the awards in your niche and the winners, agencies, values and recompetes arrive in your sheet, CRM, Slack or agent as they are reported.
- M3QDM72NME75UEI
- Minneapolis, MNLocation
- Small BusinessBusiness size
- 3Contract awards
- $7.5 millionObligated
- 2024-06-20First action in window
- 2026-04-27Latest action
Where the work is
NAICS codes, with the other winners in each.
| NAICS | Industry | Awards | Obligated |
|---|---|---|---|
| 541715 | Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) | 2 | $7.5 million |
| 541714 | Research and Development in Biotechnology (except Nanobiotechnology) | 1 | $0 |
Buying agencies
| Agency | Awards | Obligated |
|---|---|---|
| Department of Health and Human Services | 3 | $7.5 million |
Obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2024 | $0 |
| FY2026 | $7.5 million |
Contract awards
All 3 awards in fiscal years 2024 to 2027.
| Award ID | Agency | Type | NAICS | What it buys | Obligated in window | Award value | Starts | Ends | Place of performance | Source |
|---|---|---|---|---|---|---|---|---|---|---|
| 75A50126C00005 | Department of Health and Human Services | Definitive Contract | 541715 | THE PURPOSE OF THIS AWARD IS TO ADVANCE THE DEVELOPMENT OF ISOLA'S NEBULIZATION THERAPY, A MEDICAL COUNTERMEASURE DESIGNED TO PREVENT AND TR | $7,485,417 | $7,485,417 | May 1, 2026 | October 31, 2028 | Minneapolis, MN | usaspending.gov |
| 75A50123C00031 | Department of Health and Human Services | Definitive Contract | 541714 | R&D FOR ENDOBRONCHIAL LAVAGE (EBL) TO PREVENT AND TREAT LUNG DAMAGE FROM PULMONARY CHEMICAL AGENTS AOI #15: REDIRECT (REPURPOSING DRUGS IN R | $0 | $749,999 | July 12, 2023 | July 11, 2025 | Minneapolis, MN | usaspending.gov |
| 75N91022C00018 | Department of Health and Human Services | Definitive Contract | 541715 | PHASE I -TOPIC 431 - DRUG DELIVERY BY ENDOESOPHAGEAL LAVAGE (EEL) TO TREAT ESOPHAGEAL CANCER | $0 | $455,000 | September 15, 2022 | March 14, 2025 | Minneapolis, MN | usaspending.gov |
Also on SpecStream
- All recipients under NAICS 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- All recipients under NAICS 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Open opportunities under NAICS 541715
- Open opportunities under NAICS 541714
Public U.S. federal spending data (U.S. Department of the Treasury). Obligations are the contract actions dated in fiscal years 2024 to 2027 of the USAspending.gov award archive of 2026-10-06; a contract's total value is its current value as USAspending reports it, including earlier years. Recipients are matched on their SAM.gov UEI, never on the name, and are shown as the government prints them. Sole proprietorships and opted-out entities count in the totals and are not named. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.